Lead Editor:
Professor Gregory T. MacLennan,
Case Western Reserve University,
United States
Metastasis is still an immense challenge in the treatment of cancer. Whilst recent years have seen great advances in cancer diagnosis and treatment, metastasis is still difficult to treat. For cancer cells to successfully detach from the primary tumor and spread around the body, cell-to-cell adhesion must break down. Tight junctions are the first cell adhesion complex to be dismantled during metastasis formation and are therefore fundamental for cancer development. The cellular structure of tight junctions has been increasingly described to be important in cancer disease progression and therefore it is identified as a potential target for treatment and means of drug delivery. Several questions still need to be fully addressed to improve our understanding of the role of tight junctions in cancer metastasis. These include the underlying molecular mechanisms within the cancer cell itself, and also how these mechanisms influence other cell types involved in the metastatic process. Due to their prominent role in cancer development, individual tight junctions have been increasingly reported to be potential diagnostic markers or possible targets for therapy. Moreover, tight junction complexes are crucial to the efficacy of drug therapies, as they can regulate the permeability and bioavailability of the drugs, and penetration of barriers such as the blood-brain barrier.
Submission deadline:
17/05/2026
|
Views:
